Mizuho Securities USA’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Mizuho Securities USA’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,136	Closed	-$192K	–	243
2022 Q3	$192K	Buy	+19,136	New	+$191K	0.03%	198

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Mizuho Securities USA's EUCR Position: Q4 2022 in Review

Mizuho Securities USA sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 19,136 shares — an estimated $192K sold.

Mizuho Securities USA first reported a position in EUCR in Q3 2022 and held it in 1 quarter. The position peaked at $192K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Mizuho Securities USA reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Mizuho Securities USA sold 19,136 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $192K.
Mizuho Securities USA first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2022 and held it in 1 quarter.
Mizuho Securities USA's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $192K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Mizuho Securities USA's 13F filing for Q4 2022, filed 3 Feb 2023.